2025 HIV Treatment and Prevention Agents Hospitals 
Pharmaceutical Technology
JUNE 11, 2025
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Gilead said it is “committed to working with regulatory authorities to resolve the issues underlying the clinical hold” Credit: Melnikov Dmitriy via Shutterstock. Gilead is considered the leading big pharma in HIV treatments.
Pharmacy Times
JUNE 10, 2025
The convenience of once-daily dosing and a rapid IV bolus administration may offer workflow efficiencies in hospital or surgical settings, where minimizing polypharmacy and streamlining medication administration are important goals. 2 REFERENCES 1.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 16, 2025
SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.
Putting Patients First Blog
NOVEMBER 12, 2024
Recognizing PrEP as a preventive service rather than as indicative of an active medical condition, as HHS proposes, could help address the current risk selection seen in the market. Clear guidance on the treatment of rebates within the ACF will help avoid distortions in pricing and prevent patients from bearing disproportionate costs.
ID Stewardship
DECEMBER 11, 2024
I wonder if this will cause us to be more fragmented as a group in 2025 and if Bluesky will really have sticking power. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | NEJM PURPOSE 1 RCT : No participants receiving twice-yearly lenacapavir acquired HIV infection. Mastodon sure did not.
Expert insights. Personalized for you.
52 
Let's personalize your content